• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
3-Bromo-4-fluorobenzaldehyde
5-Methyl-1,3,4-oxadiazol2(3H)-one
4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride
4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine
3-Pyridinecarboxaldehyde
Ethyl 3 Fluorobenzoate

Russians Threaten to Sue Over Vaccine Switch-Up — Reports

firstwordpharmaJune 22, 2021

Tag: COVID-19 , Vaccine , Sputnik V

Several Russian volunteers who claim they were given a less effective COVID-19 vaccine instead of the Sputnik V vaccine are considering pursuing legal action, as reported The Moscow Times on Monday.

Russians Threaten to Sue Over Vaccine Switch-Up — Reports

Seven patients said they were either misled into thinking they had received Sputnik V or met with a lack of Sputnik V doses at their vaccination sites, and were inoculated with EpiVacCorona.

Vektor Institute, which developed EpiVacCorona last year, said recently that nearly half of EpiVacCorona recipients lacked antibodies nine months after receiving the vaccine.

Russian health officials previously said that EpiVacCorona had 100% efficacy, according to the news source.

Previous:US approval for OTC use of Bayer’s Astepro

Next:Novartis’ radioligand therapy granted US Breakthrough Therapy Designation

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

Russians Threaten to Sue Over Vaccine Switch-Up — Reports | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

You may like
More>>

Hualan Biological inactivated influenza vaccine

Hualan Biological inactivated influenza vaccine
Influenza Vaccine(Split Virion),Inactivated by Hualan Bio

Influenza Vaccine(Split Virion),Inactivated by Hualan Bio
Vi Polysaccharide Typhoid Vaccine

Vi Polysaccharide Typhoid Vaccine
Hualan's Group ACYW135 Meningococcal Polysaccharide Vaccine

Hualan's Group ACYW135 Meningococcal Polysaccharide Vaccine
High quality of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent

High quality of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent
Hualan flu vaccine

Hualan flu vaccine
Hualan bio Inactivated Influenza Vaccine (Split virion)with stable quality

Hualan bio Inactivated Influenza Vaccine (Split virion)with stable quality
Hualan Biological Influenza Vaccine

Hualan Biological Influenza Vaccine
Haemophilus Influenza Type B Conjugate Vaccine

Haemophilus Influenza Type B Conjugate Vaccine
Qualified Trivalent Influenza Vaccine

Qualified Trivalent Influenza Vaccine

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service